This perspective summarizes the current landscape of biomedical nanotechnologies and outlines how their continued evolution positions nanomedicine as an enabling science driving the next generation of therapeutics.
A. Grattoni, Marco M. Paci, Noah Arnold et al.· Biomedical microdevices· 0 citations
By integrating DDT inhibition with biomarkers like homologous recombination deficiency and tumor mutational burden, this work can drive synthetic lethality, sensitize tumors to genotoxic agents, suppress treatment-induced mutagenesis, and potentially enhance responses to immunotherapy.
Audesh Bhat, G. Lahane, R. Pandita et al.· Trends in Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.